Table 5.

Estimation of the hazard ratio for disease-specific survival

Study	HR estimation	Co-factors	Analysis results
Herr [5]	P value, event no.	pT stage, pN stage, no. of LNs removed, no. of positive LNs	Significant
Wiesner [20]	HR, 95 % CI	No. of LNs removed, no. of positive LNs	Significant
Furukawa [21]	HR, 95 % CI	No. of positive LNs, laterality of positive LNs, adjuvant chemotherapy	Significant
Guzzo [22]	HR, 95 % CI	Age, sex, diversion type, pT stage, adjuvant chemotherapy	Not significant
May [24]	HR, 95 % CI	Age, sex, radical cystectomy time frame, pT stage, pN stage, tumor grade, concomitant carcinoma in situ, adjuvant chemotherapy, no. of LNs removed	Significant
Jensen [25]	HR, 95 % CI	Age, sex, pT stage, pN stage, metastasis above the aortic bifurcation, extracapsular extension, volume dependent LN density, diameter of largest LN, volume of metastatic LNs	Not significant
Morgan [26]	HR, 95 % CI	Age, Charlson comorbidity index, pT stage, tumor grade, no. of LNs removed, adjuvant chemotherapy, diversion type, year of surgery, surgeon volume, transfusion	Significant
Kassouf [27]	HR, 95 % CI	Age, sex, tumor grade, pT stage, margin status, lymphovascular invasion, adjuvant chemotherapy, concomitant carcinoma in situ	Significant
Masson-Lecomte [28]	P value, event no.	pT stage, extracapsular extension, adjuvant chemoethrapy	Not significant
Kwon [30]	HR, 95 % CI	pT stage, pN stage, no. of positive LNs, adjuvant chemotherapy	Not significant

HR: hazard ratio, LN: lymph node, CI: confidence interval